Letters
Bisphosphonates and gastrointestinal cancers
Authors’ reply to Abrahamsen and colleagues
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1518 (Published 12 March 2013) Cite this as: BMJ 2013;346:f1518
- Yana Vinogradova, research fellow in medical statistics1,
- Carol Coupland, associate professor and reader in medical statistics1,
- Julia Hippisley-Cox, professor of clinical epidemiology and general practice1
- 1Division of Primary Care, University Park, Nottingham NG2 7RD, UK
- yana.vinogradova{at}nottingham.ac.uk
Pazianas and colleagues’ study did show a 31% reduced risk of incident colorectal cancer in alendronate users compared with non-users (adjusted hazard ratio 0.69, 95% CI 0.60 to 0.79),1 2 as we noted.3 The alendronate group in table 2, however, included all women with one or more prescription for alendronate, and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.